PAG
SLNO

Private Advisor Group’s Soleno Therapeutics SLNO Stock Holding History

Private Advisor Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-67
Closed -$2K – 3132
2020
Q2 		$2K Buy
+67
New +$2.9K ﹤0.01% 3605

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Private Advisor Group's SLNO Position: Q3 2020 in Review

Private Advisor Group sold out of Soleno Therapeutics (SLNO) in Q3 2020, closing a stake of 67 shares — an estimated $2K sold.

Private Advisor Group first reported a position in SLNO in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 66 funds tracked by Wall St. Rank hold SLNO as of Q3 2020.

  • Private Advisor Group reported no remaining Soleno Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 67 Soleno Therapeutics shares in Q3 2020, an estimated $2K.
  • Private Advisor Group first reported a position in Soleno Therapeutics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Soleno Therapeutics position peaked at $2K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.